Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
GlobalData on MSN6 天
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults with transthyretin amyloid cardiomyopathy, or ATTR-CM.
The US Food and Drug Administration (FDA) on Friday approved Attruby (acoramidis), an orally-administered near-complete (≥90% ...
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
据生物制药公司BridgeBio于11月22日宣布，美国食品药品监督管理局（FDA）批准了Attruby (acoramidis)，用于治疗患有ATTR-CM的成年人，以减少心血管死亡和心血管相关的住院治疗。新闻稿中指出，Attruby是第一个也是唯一一个药物标签上标明TTR 接近完全稳定（≥90％） 的药物。
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis) to treat adults with ...
BridgeBio Pharma的Attruby提前获批和强有力的标签，加上其有利的定价和预期的广泛使用，表明公司的市场表现前景乐观。该药物在其治疗领域对患者护理和治疗选择的潜在重大影响，现在成为投资者和行业观察者关注的焦点。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈